GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Raptor Pharmaceutical Corp (NAS:RPTP) » Definitions » Owner Earnings per Share (TTM)

Raptor Pharmaceutical (Raptor Pharmaceutical) Owner Earnings per Share (TTM) : 0.00 (As of Jun. 2016)


View and export this data going back to 1999. Start your Free Trial

What is Raptor Pharmaceutical Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Raptor Pharmaceutical's Owner Earnings per Share (TTM) ended in Jun. 2016 was $0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Raptor Pharmaceutical's Owner Earnings per Share (TTM) or its related term are showing as below:



RPTP's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.03
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Raptor Pharmaceutical's Earnings per Share (Diluted) for the three months ended in Jun. 2016 was $-0.16. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2016 was $-1.03. It's PE Ratio ratio for today is At Loss.

Raptor Pharmaceutical's EPS without NRI for the three months ended in Jun. 2016 was $-0.16. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2016 was $-1.03. It's PE Ratio without NRI ratio for today is At Loss.


Raptor Pharmaceutical Owner Earnings per Share (TTM) Historical Data

The historical data trend for Raptor Pharmaceutical's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raptor Pharmaceutical Owner Earnings per Share (TTM) Chart

Raptor Pharmaceutical Annual Data
Trend Dec06 Dec07 Dec08 Aug09 Aug10 Aug11 Aug12 Dec13 Dec14 Dec15
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.11 -0.84 -1.13 -1.00 -0.77

Raptor Pharmaceutical Quarterly Data
Aug11 Nov11 Feb12 May12 Aug12 Nov12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.76 -0.74 -0.77 -1.08 -1.04

Competitive Comparison of Raptor Pharmaceutical's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Raptor Pharmaceutical's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raptor Pharmaceutical's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Raptor Pharmaceutical's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Raptor Pharmaceutical's Price-to-Owner-Earnings falls into.



Raptor Pharmaceutical Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Raptor Pharmaceutical's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -87.2
Depreciation, Depletion and Amortization 1.9
Change In Deferred Tax 0.8
5Y Average of Maintenance Capital Expenditure 1.7
Change In Working Capital -2.9
Shares Outstanding (Diluted Average) 85.4

1. Start with "Net Income" from income statement. Raptor Pharmaceutical's Net Income for the trailing twelve months (TTM) ended in Jun. 2016 was $-87.2 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Raptor Pharmaceutical's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2016 was $1.9 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Raptor Pharmaceutical's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2016 was $0.8 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $1.7 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Raptor Pharmaceutical's 5-Year Average Maintenance Capital Expenditure = $1.7 Mil

5. "Change In Working Capital" is from cashflow statement. Raptor Pharmaceutical's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2016 was $-2.9 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Raptor Pharmaceutical's Shares Outstanding (Diluted Average) for the months ended in Jun. 2016 was 85.417 Mil.

Raptor Pharmaceutical's Onwer Earnings Per Share for Jun. 2016 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -87.195 +1.896+0.783
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-1.7172771293281+-2.871)/85.417
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=9.00/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Raptor Pharmaceutical Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Raptor Pharmaceutical's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Raptor Pharmaceutical (Raptor Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. It is a biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product PROCYSBI cysteamine bitartrate, delayed-release capsules received marketing approval from the U.S. Food and Drug Administration on April 30, 2013 for the management of nephropathic cystinosis in adults and children six years and older. The European equivalent, PROCYSBI gastro-resistant hard capsules of cysteamine, received marketing authorization on September 6, 2013 from the European Commission, as an orphan medicinal product for the management of nephropathic cystinosis for marketing in the European Union. PROCYSBI received 7 years and 10 years of market exclusivity as an orphan drug in the U.S. and the EU, respectively. PROCYSBI is an approved therapy for the management of nephropathic cystinosis, a rare, life-threatening metabolic lysosomal storage disorder that causes the rapid, toxic accumulation of cystine in all cells, tissues and organs in the body. PROCYSBI capsules contain cysteamine bitartrate in the form of microspheronized beads that are individually coated to create delayed and extended-release properties, allowing patients to maintain consistent therapeutic systemic drug levels over a 12-hour dosing period. Cysteamine is a molecule generated in the cell during the metabolism of cysteine. The Company's pipeline products include; its proprietary delayed-release form of cysteamine, or RP103. The Company currently has product candidates in clinical development designed to potentially treat Huntington's disease, Non-alcoholic fatty liver disease, Leigh syndrome and other mitochondrial disorders and aldehyde dehydrogenase deficiency. The Company's preclinical programs are based upon bioengineered novel drug candidates that are designed to target cancer and other diseases. Its other clinical-stage product candidates include: Convivia its proprietary oral formulation of 4-methylpyrazole, for the potential management of acetaldehyde toxicity due to alcohol consumption by individuals with aldehyde dehydrogenase, or ALDH2, deficiency, an inherited metabolic disorder. With respect to any of the Company's product candidates for which it obtain FDA approval, it will be subject to ongoing FDA obligations and continued regulatory review, which may result in additional expense.
Executives
Raymond Anderson director C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Krishna R Polu officer: Chief Medical Officer C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Michael P Smith officer: Chief Financial Officer 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Llew Keltner director 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Christopher M Starr director C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
David Happel officer: Chief Commercial Officer 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Julie Smith director, officer: President and CEO C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Erich Sager director 9 COMMERCIAL BLVD., SUITE 200, NOVATO CA 94949
Georgia Erbez officer: Chief Financial Officer 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Vijay B Samant director 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Patrice Rioux other: CMO, Raptor Therapeutics C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091

Raptor Pharmaceutical (Raptor Pharmaceutical) Headlines

No Headlines